Friday, July 10, 2026

pharma · Asthma · Type 2 Diabetes

AstraZeneca

AstraZeneca is a pharma organization headquartered in Södertälje, SE. Primary therapeutic focus areas include Asthma, Type 2 Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease,

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
129
Drugs
77
Patents
25
Clinical program

D9311L00001

Approved · small molecule · Advanced or recurrent endometrial cancer

D9311L00001 for Advanced or recurrent endometrial cancer is a Approved program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

← All AstraZeneca projects Approved small molecule active

Internal code D9311L00001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AstraZeneca
Phase
Approved
Modality
small_molecule
Indication
Advanced or recurrent endometrial cancer
Status
active
Trials
1